Tag: Cancer
-
Weekly Symptom Monitoring Improves Quality of Life in Cancer
In adult patients undergoing cancer treatment, weekly electronic symptom monitoring significantly improved quality of life, according to a recent study published in JAMA.
-
Dual Function Found for mRNA Modifier
An enzymatic modifier of messenger RNA has different functions depending on its location, according to a recent study.
-
Epigenetic Biomarkers Predict CVD Risk
A new study provides evidence that blood epigenetic biomarkers contain “snapshots” of past cardiovascular health exposures and behavior at the molecular level.
-
Identifying Protein Interactions that Promote Cancer Growth
Proteins gain new interactions that are potentially oncogenic and could drive cancer development and growth, according to a recent study.
-
Combination Treatment May Improve Quality of Life in Kidney Cancer
Patients with advanced kidney cancer who received a new combination treatment reported improved health-related quality of life outcomes, according to a Northwestern Medicine study.
-
Calcium Channel Blockers May Improve Chemotherapy Response
Calcium channel blockers may improve treatment for patients with pancreatic cancer receiving chemotherapy, according to a recent study.
-
Deep-learning Empowers Discovery of New Genetic Mutation in Cancer
A deep learning model has discovered genetic variations in cancer that are undetectable in traditional genome sequencing.
-
Northwestern Faculty Elected to Society for Clinical Trials Board
Jody Ciolino, PhD, and Masha Kocherginsky, PhD, faculty in the Department of Preventive Medicine Division of Biostatistics, were elected to the Board of Directors for the Society for Clinical Trials (SCT).
-
Genome-wide Intricacies of Cancer Inhibitor Untangled
A newly discovered inhibitor of a common cancer-causing protein operates selectively, reducing expression of genes that fuel rampant cell proliferation, and altering the epigenome, according to a recent study.
-
Mixed Results from Prostate Cancer Drug
A new androgen biosynthesis inhibitor drug improved progression-free survival in prostate cancer but did not improve overall survival compared to current therapies.
